Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL

被引:181
作者
Aktas, O
Smorodchenko, A
Brocke, S
Infante-Duarte, C
Topphoff, US
Vogt, J
Prozorovski, T
Meier, S
Osmanova, V
Pohl, E
Bechmann, I
Nitsch, R
Zipp, F
机构
[1] Humboldt Univ, Charite, Neurosci Res Ctr, Inst Neuroimmunol, D-10098 Berlin, Germany
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91120 Jerusalem, Israel
[3] Humboldt Univ, Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10098 Berlin, Germany
关键词
D O I
10.1016/j.neuron.2005.03.018
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Here, we provide evidence for a detrimental role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in neural death in T cell-induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Clinical severity and neuronal apoptosis in brainstem motor areas were substantially reduced upon brain-specific blockade of TRAIL after induction of EAE through adoptive transfer of encephalitogenic T cells. Furthermore, TRAIL-deficient myelin-specific lymphocytes showed reduced encephalitogenicity when transferred to wildtype mice. Conversely, intracerebral delivery of TRAIL to animals with EAE increased clinical deficits, while naive mice were not susceptible to TRAIL. Using organotypic slice cultures as a model for living brain tissue, we found that neurons were susceptible to TRAIL-mediated injury induced by encephalitogenic T cells. Thus, in addition to its known immunoregulatory effects, the death ligand TRAIL contributes to neural damage in the inflamed brain.
引用
收藏
页码:421 / 432
页数:12
相关论文
共 65 条
[1]   Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis [J].
Aktas, O ;
Prozorovski, T ;
Smorodchenko, A ;
Savaskan, NE ;
Lauster, R ;
Kloetzel, PM ;
Infante-Duarte, C ;
Brocke, S ;
Zipp, F .
JOURNAL OF IMMUNOLOGY, 2004, 173 (09) :5794-5800
[2]   Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin [J].
Aktas, O ;
Waiczies, S ;
Smorodchenko, A ;
Dörr, J ;
Seeger, B ;
Prozorovski, T ;
Sallach, S ;
Endres, M ;
Brocke, S ;
Nitsch, R ;
Zipp, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :725-733
[3]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]   Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease [J].
Bjartmar, C ;
Wujek, JR ;
Trapp, BD .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) :165-171
[5]  
Brocke Stefan, 1996, Methods (Orlando), V9, P458, DOI 10.1006/meth.1996.0053
[6]   Mechanisms of immune injury in multiple sclerosis [J].
Brosnan, CF ;
Raine, CS .
BRAIN PATHOLOGY, 1996, 6 (03) :243-257
[7]   Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice [J].
Cretney, E ;
Takeda, K ;
Yagita, H ;
Glaccum, M ;
Peschon, JJ ;
Smyth, MJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (03) :1356-1361
[8]   Normal thymocyte negative selection in TRAIL-deficient mice [J].
Cretney, E ;
Uldrich, AP ;
Berzins, SP ;
Strasser, A ;
Godfrey, DI ;
Smyth, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (03) :491-496
[9]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[10]   Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].
DegliEsposti, MA ;
Smolak, PJ ;
Walczak, H ;
Waugh, J ;
Huang, CP ;
DuBose, RF ;
Goodwin, RG ;
Smith, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170